Risques des associations thérapeutiques (notice n° 1727446)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02721cam a2200265 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20260322002902.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Altwegg, Romain |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Risques des associations thérapeutiques |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2024.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 85 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Therapeutic combinations in the management of patients with IBD are increasingly used, either for their effectiveness on digestive damage, or to treat an associated rheumatic disease or extra-digestive manifestations. However, these combinations of treatments are often associated with an increased risk of infection or cancer. Thus, the combotherapy of an anti-TNF and a thiopurine is associated with an increased risk of severe infections and an increased risk of lymphomas compared to the use of an anti-TNF or a thiopurine monotherapy. The combotherapy of vedolizumab or ustekinumab and a thiopurine is not associated with an increased risk of severe infections or cancer. The paucity of long-term data concerning combination therapies and the heterogeneity of treatment combinations do not make it possible to analyze the increased risk of infection or carcinology. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Les associations thérapeutiques dans la prise en charge des patients atteints de MICI sont de plus en plus fréquentes, soit pour leur efficacité sur l’atteinte digestive, soit pour traiter une maladie rhumatismale associée ou des manifestations extra-digestives. Cependant, ces associations de traitements exposent à un surrisque infectieux ou carcinologique. Ainsi, la combothérapie d’un anti-TNF et d’une thiopurine est associée à une augmentation du risque d’infections sévères et à une augmentation du risque de lymphomes par rapport à l’utilisation d’un anti-TNF ou d’une thiopurine en monothérapie. La combothérapie avec le védolizumab ou l’ustékinumab avec un immunosuppresseur n’a pas démontré de surrisque infectieux ou carcinologique. Le peu de données à long terme concernant les combiothérapies et l’hétérogénéité des associations de traitements ne permet pas d’analyser le surrisque infectieux ou carcinologique pour l’instant. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | combothérapie |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | maladies inflammatoires chroniques de l’intestin |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | risques carcinologiques |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | risques infectieux |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | carcinological risks |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | chronic inflammatory bowel disease |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | combotherapy |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | infectious risks |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hépato-Gastro & Oncologie Digestive | 31 | 8 | 2024-10-02 | p. 828-833 | 2115-3310 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://stm.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2024-8-page-828?lang=fr&redirect-ssocas=7080">https://stm.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2024-8-page-828?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux